<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200627047934N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-07</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Effects of Betamethasone In Total Knee Arthroplasty</public_title>
      <acronym>MCPI = Multimodal Cocktail Periarticular Injection           TKA = Total Knee Arthroplasty</acronym>
      <scientific_title>Evaluating The Results Of Addition Of Betamethasone To Multimodal Cocktail Periarticular Injection In Bilateral Total Knee Arthroplasty</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49265</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We divide patients by randomization with 4 blocks into groups A and B. Group A includes patients who are injected with a cocktail containing betamethasone in their right knee. In group B, a cocktail containing betamethasone is injected into the left knee. On the morning of the operation, the envelope containing the patient's group will be given to the surgeon, Blinding description: Patients, researchers, physiotherapists, and all nursing staff are unaware of these groupings (A and B) (and the study is double blind). Because the surgeon is unaware of the groupings, he will have no role in postoperative care. After collecting all the data, the information will be analyzed.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Bilateral osteoarthritis of knee.</hc_freetext>
      <i_freetext>Intervention 1: We divide patients by randomization with 4 blocks into groups A and B. Group A includes patients who are injected with a cocktail containing betamethasone in their right leg. In group B, a cocktail containing betamethasone is injected into the left leg. On the morning of the operation, the envelope containing the patient's group will be given to the surgeon. Half an hour before the operation, all patients will be injected with 1 g of intravenous Tranexamic acid, and after the operation, 500 mg of BD Tranexamic acid capsules will be given for 5 days. All patients are given 1 g of intravenous cefazolin before surgery (2 g if they weigh more than 80 kg) and 1 g of Tds after surgery. General anesthesia will be used for all patients. All joint replacement procedures will be performed using the Medial Para-Petlar Surgery Technique.Method of classification and injection of cocktails: In the knee of the intervention, 500 mg/5 ml Tranexamic acid , 20 mg of Bupivacaine, 30 mg of Ketorolac and 6 mg of Betamethasone LA (Betamethasone acetate 3mg + Betamethasone 3 mg) are combined . The final volume of the cocktail will reach 45ml with normal saline and will be injected in two steps: The first injection is before the protheses are placed, during which 30ml of the cocktail is applied to all the surrounding tissues except the posterolateral capsule (to prevent temporary paralysis of Proneal nerve) will be performed. The next injection contains the remaining 15 ml of the cocktail, which will be applied to the edges of the wound when it closing. Antithrombotic treatment with 40 mg subcutaneous Enoxaparin is started the day after surgery. The tourniquet is used in all patients and the drain is going out 24 hours after the operation. drawing Bandage is used compressively. Patients will walk from the night of the operation and if they do not tolerate the day after the operation. For pain control in the first 48 hours, 5mg of morphine PRN is prescribed a maximum of 3 times, 1g of Apotel ampoules TDS  and one Ketorolac ampoule BD. Pain control will be performed after 48 hours with 15 mg of Meloxicam daily and 1g of Acetaminophen 3 times a day. To compare the two cocktails, we will divide the knees into two groups A (in which a cocktail containing Betamethasone is injected) and B (in which a cocktail without Betamethasone is injected). Intervention 2: Control Knee: In this group, betamethasone-free injectable cocktail (500 ml / mg 5 mg tracenamic acid, 20 mg bupivacaine, 30 mg ketorolac) is made. The final volume of the cocktail with normal saline will reach 45ml. The rest of the steps will be similar to the intervention knee.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farivar Bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khatam al Anbya Hospital, Daneshgah Blvd.</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614871151</zip>
        <telephone>+98 23 3239 2661</telephone>
        <email>Dr.mamad73@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farivar Bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khatam al Anbya Hospital, Daneshgah Blvd.</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614871151</zip>
        <telephone>+98 912 714 0282</telephone>
        <email>Dr.mamad73@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People aged 50 to 90 years
Having advanced osteoarthritis of both knees</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>90 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People who did not agree to study and use their information
Contraindications to the use of the studied drugs (including known allergies or intolerance to one of the drugs, fungal infections, having heart, liver, brain, kidney disease and inflammatory diseases of the joints, people with bleeding disorders, gastrointestinal bleeding, Asthma, glaucoma, cataracts and diabetic patients)
Patients weighing more than 100 kg
Patients with neuropathic pain and sensory disturbances in the foot
Patients with a history of knee surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bilateral primary osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>We divide patients by randomization with 4 blocks into groups A and B. Group A includes patients who are injected with a cocktail containing betamethasone in their right leg. In group B, a cocktail containing betamethasone is injected into the left leg. On the morning of the operation, the envelope containing the patient's group will be given to the surgeon. Half an hour before the operation, all patients will be injected with 1 g of intravenous Tranexamic acid, and after the operation, 500 mg of BD Tranexamic acid capsules will be given for 5 days. All patients are given 1 g of intravenous cefazolin before surgery (2 g if they weigh more than 80 kg) and 1 g of Tds after surgery. General anesthesia will be used for all patients. All joint replacement procedures will be performed using the Medial Para-Petlar Surgery Technique.Method of classification and injection of cocktails: In the knee of the intervention, 500 mg/5 ml Tranexamic acid , 20 mg of Bupivacaine, 30 mg of Ketorolac and 6 mg of Betamethasone LA (Betamethasone acetate 3mg + Betamethasone 3 mg) are combined . The final volume of the cocktail will reach 45ml with normal saline and will be injected in two steps: The first injection is before the protheses are placed, during which 30ml of the cocktail is applied to all the surrounding tissues except the posterolateral capsule (to prevent temporary paralysis of Proneal nerve) will be performed. The next injection contains the remaining 15 ml of the cocktail, which will be applied to the edges of the wound when it closing. Antithrombotic treatment with 40 mg subcutaneous Enoxaparin is started the day after surgery. The tourniquet is used in all patients and the drain is going out 24 hours after the operation. drawing Bandage is used compressively. Patients will walk from the night of the operation and if they do not tolerate the day after the operation. For pain control in the first 48 hours, 5mg of morphine PRN is prescribed a maximum of 3 times, 1g of Apotel ampoules TDS  and one Ketorolac ampoule BD. Pain control will be performed after 48 hours with 15 mg of Meloxicam daily and 1g of Acetaminophen 3 times a day. To compare the two cocktails, we will divide the knees into two groups A (in which a cocktail containing Betamethasone is injected) and B (in which a cocktail without Betamethasone is injected).</i_keyword>
      <i_keyword>Control Knee: In this group, betamethasone-free injectable cocktail (500 ml / mg 5 mg tracenamic acid, 20 mg bupivacaine, 30 mg ketorolac) is made. The final volume of the cocktail with normal saline will reach 45ml. The rest of the steps will be similar to the intervention knee.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score. Timepoint: It is measured at hours 6, 18, 24, 48 and on days 7, 14 and 60 after surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Knee range of motion. Timepoint: It will be measured at 24, 48 hours and 7 and 60 days after surgery. Method of measurement: Gonia meters.</prim_outcome>
      <prim_outcome>Oxford Knee Score. Timepoint: It will be checked before the operation and on the 60th day after the operation. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Wound complications. Timepoint: At any time of the visit. Method of measurement: Observation and examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patients' satisfaction with pain control. Timepoint: It will be asked at hours 24, 48 and on days 7 and 60 after the operation. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-09</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University - Shahroud Branch</contact_name>
        <contact_address>Central building, Islamic Azad University, next to the gas station, Daneshgah Blvd., Shahroud, Semnan Shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
